|
It was reported patient came from intensive care unit (icu) in a rather critical state.The 23f sheath was used for acute myocardial infraction (ami) and a cardiogenic shock (cgs) procedure.Issue with the 23f sheath was bleeding through the valve, it was identified when sheath was inserted into the femoral vein, physician tried to stop bleeding with 0.027" wire (different vendors product), then 12f sheath, then rp pump (in that order) unsuccessfully.Only brief delay of the procedure due to bleeding, no impact on patient condition.Patient outcome is death ((b)(6) 2020), however, death is not related to device failure.Physician reported cause of patient death as ventricular tachycardia (attempts to achieve sinusrhythm were unsuccessful) followed by no output from left ventricle (lv).Additionally, the physician said that the blood loss was not contributing to the death of the patient since it was not therapeutically relevant.
|
|
The device was used in treatment.The device was not returned for analysis, as it was discarded.The investigation will focus on a review of product documentation.The device history records were reviewed to confirm that the device passed all applicable in process and final inspections.Per qa procedure abiomed introducer sheath in-process and final inspections: 12.3 vacuum leak test: perform pressure and vacuum leak test per procedure, latest revision.This procedure is performed by qa 100%.Per instructions for use (ifu): when assembling the sheath and dilator, care must be taken to insert the dilator tip straight through the center of the valve membrane in order to prevent inadvertent puncturing of the membrane.Dilators, catheters, and pacing leads should be removed slowly from the sheath.Rapid removal may damage the valve membrane resulting in blood flow through the valve.Based on the investigation, a capa is not required as findings did not identify a design, labeling or manufacturing non-conformity.The event will be re-evaluated if additional information becomes available.Oscor will continue to monitor this event type and risk.Oscor inc.Is submitting the above report to comply with 21 cfr part 803, the medical device reporting regulation.The report is based upon information obtained by oscor inc.Which the company may not have been able to investigate or verify prior to the date the report was required by fda.This report does not constitute an admission that the device, oscor inc., or its employees, caused or contributed to the event described in this report.Nor does this report reflect a conclusion by fda, oscor inc., or its employees, that the report constitutes an admission that the device, oscor inc., or its employees caused or contributed to the event described in this report.
|